N&N PHARMACARE: what changed
What changed
N&N PHARMACARE
NACE 70.200, Business and other management consultancy
filed annual accounts (NBB)
Net result for the year
€202,012
2024 · €29,634+€172,378
Equity
€236,143
2024 · €34,131+€202,012
Cash
€15,460
2024 · €9,896+€5,564
Balance sheet total
€1.1m
2024 · €1.1m-€27,274
Largest movements
Assets
- Receivables within one year -€33,150
down €33,150 (-47.4%), from €70,000 to €36,850
Equity and liabilities
- Profit (loss) carried forward +€202,012
up €202,012 (+670%), from €30,131 to €232,143
- Other debts -€196,981
down €196,981 (-59.9%), from €328,776 to €131,795
- Debts after one year -€57,965
down €57,965 (-8.4%), from €688,422 to €630,457
- Tax, wage and social debts +€18,306
up €18,306 (+146%), from €12,559 to €30,865
Income statement
- Financial income +€180,000
new in 2025: €180,000
- Financial charges +€4,806
up €4,806 (+18.2%), from €26,457 to €31,263
- Gross operating margin -€4,249
down €4,249 (-6.7%), from €63,500 to €59,251
- Taxes -€1,433
down €1,433 (-19.3%), from €7,409 to €5,976
Change in the result, 2024 to 2025
For each income-statement line you see the change as its effect on the result. Higher costs lower the result, higher income raises it.
Result 2024
€29,634
Gross operating margin
-€4,249
Other operating charges
-€0
Financial income
+€180,000
Financial charges
-€4,806
Taxes
+€1,433
Result 2025
€202,012
raises the resultlowers the result
Derived cash bridge
The bridge is derived from the 2024 and 2025 balance sheets and the 2025 result. There is no filed cash-flow statement. You see where the money came from and where it went.
From operations
+€61,067
Investment
€0
Financing
-€55,503
Cash 2024
€9,896
From operations (derived)
+€61,067
Net result for the year
+€202,012
Receivables within one year
+€33,150
Deferred charges and accrued income
-€312
Trade debts
+€4,892
Tax, wage and social debts
+€18,306
Other debts
-€196,981
Financing
-€55,503
Debts after one year
-€57,965
Current portion of long-term debt
+€2,462
Cash 2025
€15,460
brings cash intakes cash out
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €1,123,401 | €1,096,127 | -€27,274 | -2.4% |
| Fixed assets | 21/28 | €1,043,505 | €1,043,505 | = | 0.0% |
| Financial fixed assets | 28 | €1,043,505 | €1,043,505 | = | 0.0% |
| Current assets | 29/58 | €79,896 | €52,622 | -€27,274 | -34.1% |
| Amounts receivable within one year | 40/41 | €70,000 | €36,850 | -€33,150 | -47.4% |
| Trade receivables | 40 | €70,000 | €36,850 | -€33,150 | -47.4% |
| Cash at bank and in hand | 54/58 | €9,896 | €15,460 | +€5,564 | +56.2% |
| Deferred charges and accrued income | 490/1 | - | €312 | +€312 | |
| Total equity and liabilities | 10/49 | €1,123,401 | €1,096,127 | -€27,274 | -2.4% |
| Equity | 10/15 | €34,131 | €236,143 | +€202,012 | +592% |
| Contributions | 10/11 | €4,000 | €4,000 | = | 0.0% |
| Capital | 10 | €4,000 | €4,000 | = | 0.0% |
| Issued capital | 100 | €4,000 | €4,000 | = | 0.0% |
| Profit (loss) carried forward | 14 | €30,131 | €232,143 | +€202,012 | +670% |
| Amounts payable | 17/49 | €1,089,270 | €859,985 | -€229,286 | -21.0% |
| Amounts payable after more than one year | 17 | €688,422 | €630,457 | -€57,965 | -8.4% |
| Financial debts | 170/4 | €688,422 | €630,457 | -€57,965 | -8.4% |
| Amounts payable within one year | 42/48 | €400,848 | €229,527 | -€171,320 | -42.7% |
| Current portion of amounts payable after more than one year | 42 | €55,503 | €57,965 | +€2,462 | +4.4% |
| Trade debts | 44 | €4,010 | €8,902 | +€4,892 | +122% |
| Suppliers | 440/4 | €4,010 | €8,902 | +€4,892 | +122% |
| Taxes, remuneration and social security | 45 | €12,559 | €30,865 | +€18,306 | +146% |
| Taxes | 450/3 | €12,559 | €30,865 | +€18,306 | +146% |
| Other amounts payable | 47/48 | €328,776 | €131,795 | -€196,981 | -59.9% |
| Other operating charges | 640/8 | - | €0 | +€0 | |
| Gross operating margin | 9900 | €63,500 | €59,251 | -€4,249 | -6.7% |
| Operating profit (loss) | 9901 | €63,500 | €59,251 | -€4,249 | -6.7% |
| Financial income | 75/76B | - | €180,000 | +€180,000 | |
| Recurring financial income | 75 | - | €180,000 | +€180,000 | |
| Financial charges | 65/66B | €26,457 | €31,263 | +€4,806 | +18.2% |
| Recurring financial charges | 65 | €26,457 | €31,263 | +€4,806 | +18.2% |
| Profit (loss) for the period before taxes | 9903 | €37,043 | €207,988 | +€170,945 | +461% |
| Income taxes | 67/77 | €7,409 | €5,976 | -€1,433 | -19.3% |
| Profit (loss) for the period | 9904 | €29,634 | €202,012 | +€172,378 | +582% |
| Profit (loss) for the period to be appropriated | 9905 | €29,634 | €202,012 | +€172,378 | +582% |
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Compare this company with its sector.Sector benchmark
Calculation and sources
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Green is a favourable move for that line, red an unfavourable one. Prepared on 3 November 2026 via checked.be.